Vorinostat is under clinical development by Unravel Biosciences and currently in Phase I for Rett Syndrome. According to GlobalData, Phase I drugs for Rett Syndrome have a 79% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Vorinostat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Vorinostat overview
Vorinostat is under development for the treatment of Rett syndrome. It is administered through oral route. It is being developed based on BioNAV platform.
Unravel Biosciences overview
Unravel Biosciences is a drug discovery engine that identifies repurposed drugs for the treatment of rare diseases. The company employs artificial intelligence based target-agnostic drug prediction to discover the repurposed drugs and move them to clinic for commercialization. It is headquartered in Boston, Massachusetts, the US.
For a complete picture of Vorinostat’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
